Response Genetics, Inc. was founded to leverage breakthrough, patented technology for the extraction and analysis of genetic information to help physicians make informed and time-critical treatment decisions.
Response Genetics is an innovative and rapidly growing life sciences company engaged in the research and development of clinical diagnostic tests for cancer. We are driven by our mission to provide timely, accurate and validated molecular testing services to physicians and their patients, enabling personalized cancer treatment based on genetic analysis.
Fully licensed and accredited by the Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP), Response Genetics offers proprietary tests and panels for lung, colon, gastric cancer, and melanoma, as well as the FDA-cleared Tissue of Origin (TOO) test. To learn more about the technology behind each of these products please visit the Response Genetics Technology page.